tiprankstipranks
Trending News
More News >
Bayer (DE:BAYN)
XETRA:BAYN
Advertisement

Bayer (BAYN) AI Stock Analysis

Compare
791 Followers

Top Page

DE:BAYN

Bayer

(XETRA:BAYN)

Select Model
Select Model
Select Model
Neutral 45 (OpenAI - 4o)
Rating:45Neutral
Price Target:
€27.00
▼(-2.21% Downside)
Bayer's overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. The company's high leverage and negative profitability metrics pose significant financial risks. The technical analysis further indicates weak market momentum, while the valuation suggests the stock may be overvalued given its current financial state.
Positive Factors
Strong R&D Commitment
Bayer's strong focus on R&D supports innovation in pharmaceuticals and crop science, potentially leading to new products and market expansion.
Diverse Revenue Streams
Diversified revenue streams across multiple sectors reduce dependency on a single market, enhancing stability and resilience against sector-specific downturns.
High Gross Profit Margin
A strong gross profit margin indicates effective cost management and pricing power, which can support long-term profitability despite revenue challenges.
Negative Factors
Declining Revenue
Declining revenue trends pose a risk to Bayer's financial health, potentially affecting its ability to invest in growth and maintain competitive positioning.
High Leverage
High leverage increases financial risk, limiting Bayer's flexibility to invest in strategic initiatives and potentially impacting long-term financial stability.
Negative Profitability
Ongoing losses and negative profitability highlight operational inefficiencies, which could undermine Bayer's ability to sustain long-term growth and shareholder value.

Bayer (BAYN) vs. iShares MSCI Germany ETF (EWG)

Bayer Business Overview & Revenue Model

Company DescriptionBayer AG is a global life sciences company headquartered in Leverkusen, Germany, operating primarily in the sectors of pharmaceuticals, consumer health, and crop science. The company is dedicated to advancing health and nutrition through innovative products and solutions, including prescription medications, over-the-counter healthcare products, and agricultural solutions such as seeds and crop protection. Bayer's commitment to research and development drives its extensive portfolio, addressing critical health and agricultural challenges worldwide.
How the Company Makes MoneyBayer generates revenue through multiple key streams across its business segments. The Pharmaceuticals division contributes significantly by offering prescription medications in areas such as cardiology, oncology, and women's health. The Consumer Health segment includes over-the-counter products, which provide steady revenue from everyday health solutions. Additionally, the Crop Science division, which focuses on crop protection products and seeds, plays a critical role in the agricultural market. Bayer also engages in strategic partnerships and collaborations with other healthcare and agricultural firms, as well as research institutions, to enhance its product offerings and expand its market reach. The company's strong commitment to innovation and R&D enables it to develop new products that meet evolving consumer and market needs, further driving its revenue growth.

Bayer Financial Statement Overview

Summary
Bayer is facing significant financial challenges, with declining revenues and persistent losses impacting profitability. The high leverage and negative return on equity highlight financial risks, while cash flow management shows some resilience despite declining free cash flow. The company needs to address operational inefficiencies and improve profitability to enhance its financial position.
Income Statement
45
Neutral
Bayer's income statement shows significant challenges, with a negative net profit margin of -6.98% for TTM, indicating ongoing losses. Revenue has been declining, with a notable drop of 8.69% in the TTM period. The gross profit margin remains relatively strong at 53.99%, but the negative EBIT margin highlights operational inefficiencies. Overall, the company is struggling with profitability and revenue growth.
Balance Sheet
50
Neutral
The balance sheet reveals a high debt-to-equity ratio of 1.21, indicating significant leverage, which could pose financial risks. Return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. However, the equity ratio is relatively stable, suggesting a balanced asset structure. The high leverage and negative ROE are concerning, but the equity ratio provides some stability.
Cash Flow
55
Neutral
Cash flow analysis shows a decline in free cash flow growth by 12.89% in the TTM period, indicating challenges in generating cash. The operating cash flow to net income ratio is 0.29, suggesting that operating cash flow is not sufficient to cover net losses. However, the free cash flow to net income ratio of 0.66 indicates some ability to generate cash relative to net losses. Overall, cash flow management is under pressure but shows some resilience.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue46.17B46.61B47.64B50.74B44.08B41.40B
Gross Profit25.37B25.34B27.89B30.87B27.27B22.26B
EBITDA6.55B3.81B4.21B10.44B6.97B-11.48B
Net Income-3.42B-2.55B-2.94B4.15B1.00B-15.56B
Balance Sheet
Total Assets105.24B110.85B116.26B124.88B120.24B117.05B
Cash, Cash Equivalents and Short-Term Investments5.50B8.09B10.59B10.15B7.74B11.88B
Total Debt38.43B40.81B44.79B41.32B39.53B41.55B
Total Liabilities74.74B78.81B83.18B85.95B87.07B86.35B
Stockholders Equity30.37B31.91B32.93B38.77B33.02B30.52B
Cash Flow
Free Cash Flow4.59B4.59B2.37B4.14B2.48B2.48B
Operating Cash Flow7.15B7.37B5.12B7.09B5.09B4.90B
Investing Cash Flow2.78B164.00M-4.01B-2.38B855.00M-4.07B
Financing Cash Flow-8.89B-7.18B-679.00M-4.22B-5.64B423.00M

Bayer Technical Analysis

Technical Analysis Sentiment
Positive
Last Price27.61
Price Trends
50DMA
27.88
Negative
100DMA
27.51
Positive
200DMA
25.04
Positive
Market Momentum
MACD
-0.10
Negative
RSI
49.21
Neutral
STOCH
74.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BAYN, the sentiment is Positive. The current price of 27.61 is below the 20-day moving average (MA) of 27.85, below the 50-day MA of 27.88, and above the 200-day MA of 25.04, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 49.21 is Neutral, neither overbought nor oversold. The STOCH value of 74.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:BAYN.

Bayer Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
$55.26B25.5811.75%1.92%5.85%16.20%
€13.68B21.054.83%3.06%0.53%23.79%
€15.08B100.805.01%0.37%5.82%59.90%
€27.32B24.537.30%2.04%-0.59%
€50.02B17.4710.08%1.92%1.67%9.02%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
€27.29B-7.98-10.35%0.40%-1.99%-169.98%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:BAYN
Bayer
27.61
2.18
8.59%
DE:FME
Fresenius Medical Care AG & Co. KGaA
46.69
10.19
27.92%
DE:FRE
Fresenius SE & Co. KGaA
49.39
16.11
48.41%
DE:MRK
Merck KGaA
114.40
-35.18
-23.52%
DE:SRT
Sartorius
191.80
-2.58
-1.33%
DE:SHL
Siemens Healthineers AG
49.48
1.10
2.27%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 21, 2025